Page 99 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 7. Eligibility criteria for enrollment in protocols with palliative intent in chronological order of starting enrollment year (continued)
Center, Country Term Age PSA Gleason score # biopsy Imaging Stage Behavioral indication (other than
[Pubmed ID] used (yr) (ng/mL) cores /% patients’ choice or preference)
Enrollment cores
years
Hospitals in WW – <50 – – Bone scan – –
Manchester negative
region, UK 148
[11711356]

NR
Univ. of Florida, EM – – – – – “Low-stage, Severe medical condition with a life
US 149 low-grade expectancy of <10 yr
[18263992] disease”

2003-2006
WW = watchful waiting; EM = expectant management; NR = not reported; DT = doubling time; mo = month(s); PAP = prostate acid phosphatase; PSA = prostate specific antigen;
TRUS = Transrectal ultrasound; CT = computerized tomography; PSA = prostate-specific antigen; TNM = tumor-node-metastasis system; US = ultrasound; yr = year(s); ED =
erectile dysfunction; SPCG-4 = Scandinavian Prostate Cancer Group Study Number 4; PIVOT = Prostate Cancer Intervention Versus Observation Trial; VA = Veterans Affair
a ERSPC-screening protocol, carried over to AS selection criteria because patients were identified from ERSPC
b University Hospital of South Manchester, Withington Hospital, Christie Hospital; Hope Hospital

52